The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.

To provide a monoclonal antibody against canine CD20 having a more excellent effect than existing antibodies.

The present invention provides a monoclonal antibody or antibody fragment against canine CD20 that has a heavy chain variable region consisting of an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 1, and a light chain variable region consisting of an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 2, and that has a light chain constant region consisting of an amino acid sequence of SEQ ID NO: 3 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 3.

The present invention generally pertains to methods of preventing disulfide scrambling in non-reducing liquid chromatography-mass spectrometry analysis of a protein of interest. In particular, the present invention pertains to the addition of cystamine to a non-reducing liquid chromatography-mass spectrometry analysis of an antibody to prevent disulfide scrambling.

The present inventions provide methods to control the heterogeneity of Fc-containing proteins, such as antibodies produced in cell culture, particularly mammalian cell culture by controlling culture pCO.sub.2, as well as products produced by these methods. Among other things, the inventions provide for lowering the percentage of acidic charge variants in antibody products. Proteins that comprise Fc moieties include but are not limited to Fc-containing proteins, such as antibodies and antibody derivatives, and fragments of both.

The present invention relates, in part, to agents, chimeric proteins and protein complexes that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents, chimeric proteins and protein complexes and their use in the treatment of various diseases.

Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.

The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.

Methods for using anti-B7-H4 antibodies and antibody-drug conjugates, including anti-B7-H4 antibody-drug conjugates, to inhibit proliferation of a cell, such as a B7-H4-expressing cell, as well as for the treatment of cancers, such as, e.g., B7-H4-associated solid tumors and breast cancer (e.g., locally advanced or metastatic breast cancer), are provided.

Provided herein are cell penetrating conjugates. The conjugates include non-cell penetrating proteins connected through a phosphorothioate nucleic acid, wherein the phosphorothioate nucleic acid enhances intracellular delivery of the non-cell penetrating proteins. Also provided are methods and kits including the conjugates provided herein.

The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.